Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable. We used ELISA to analyze the levels of soluble PD-L1 (suPD-L1) in bone marrow (BM) plasma from 61 patients with MM at...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Huang, Shang-Yi, Lin, Hsiu-Hsia, Lin, Chung-Wu, Li, Chi-Cheng, Yao, Ming, Tang, Jih-Luh, Hou, Hsin-An, Tsay, Woei, Chou, Sheng-Je, Cheng, Chieh-Lung, Tien, Hwei-Fang
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5308741/
https://ncbi.nlm.nih.gov/pubmed/27566569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11519
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires